ESSO Advanced Course on the Treatment of Peritoneal Surface Malignancy

In partnership with Ziekenhuis Oost-Limburg and Universiteit Hasselt, Biomed Research Institute

Genk (BE), 12-14 October 2017



Interactive case presentation on colorectal peritoneal surface malignancy

Marc POCARD

Paris Diderot University – INSERM – AP-HP

France









Links of interest – Pr Marc Pocard


- 2012 2017:
- Honorary:
 Gamida, Léo-Pharm, Pfizer, Novartis, Sanofi, Roche
- Award congress laboratory research programe:
 Capnomed, Clerad, Ethicon, Fujinon, Gamida,
 INSERMTransfert, Plasma-jet, Roche, Sanofi, Sofra-médical,
 STAGO, Storz, Rand



- No medical and surgical history
- No familial history
- Rectal hemorrhages and melena from 3 months
- General Condition Altered : karnofsky 60
- CT Scanner: tumor of the colon and suspicion of peritoneal metastasis

November 2007







- No medical and surgical history
- No familial history
- Rectal hemorrhages and melena from 3 months
- General Condition Altered : OMS 2
- CT Scanner: tumor of the colon and suspicion of peritoneal metastasis



- No medical and surgical history
- No familial history
- Rectal hemorrhages a
- General Condition Al
- CT Scanner: tumor o peritoneal metastasis

What do we do

I: I need a tumor biopsy

2: I perform a colonoscopy

3: I perform a CT for peritoneal biopsy

4: I perform a per rectal biopsy of a nodule on the cul de sac of Douglas



I: I need a tumor biopsy

2: I perform a colonoscopy

- No medical and surgical history
- No familial history
- Rectal hemorrhages and melena
- General Condition Altered : OMS 2
- CT Scanner: tumor of
- Short colonoscopy: adenocarcinoma



- Colon carcinoma
- No occlusion
- Altered general status
- KRAS wild type
- CEA = 29,4 (normal < 5)
- T4 on CT
- and MI with peritoneal metastasis



A Young man of 3

- Colon carcinoma
- No occlusion
- Altered general statu
- KRAS wild type
- CEA = 29,4 (norma
- T4 on CT
- and MI with periton

I: surgery Hartman procedure, no CRS

2: chemotherapy, FOLFOX and antiangiogenic

3: surgery for CRS and HIPEC

4: chemotherapy, FOLFIRI and anti EGFR

5: chemotherapy, FOLFOXIRI and Bevacizumab




- Colon carcinoma
- No occlusion
- Altered general status
- KRAS wild type
- CEA = 29,4 (normal < 5)
- T4 on CT
- and MI with peritoneal metastasis

4: chemotherapy, FOLFIRI and anti EGFR




- January : came back in emergency
- Occlusive syndrome abdomen bloated as a whole with sensitivity in right iliac fossa














- Do we operate ?
- Laparoscopy or coelioscopy or elective laparotomy ?
 - No operation

Strategy



I: surgery Hartman procedure

2: no surgery stent placement

3: surgery for CRS and HIPEC

4: surgery with only colostomy

5: chemotherapy, FOLFOXIRI and Bevacizumab



- we operate
 - PCI at 19
- Moderated ascitis
 - CRS is possible
- No liver metastasis

Strategy



- we operate
 - PCI at 19
- Moderated ascitis
 - CRS is possible
- No liver metastasis

I: surgery Hartman procedure

2: no surgery stent placement

3: surgery for CRS and HIPEC

4: surgery with only colostomy

5: chemotherapy, FOLFOXIRI and Bevacizumab



- we operate
- PCI at 19 25?
- Moderated ascitis
 - CRS is possible
- No liver metastasis

- Strategy
- Near-upstream bypass colostomy
- No CRS

Pulmonary embolism at Day 4
Rest of the post operative course uneventful



I: chemotherapy, FOLFOX and anti angiogenic

2: chemotherapy, FOLFIRI and anti EGFR

3: chemotherapy, FOLFOXIRI



- we operate
- PCI from 19 25?
- Moderated ascitis
 - CRS is possible
- No liver metastasis

- Strategy
- Near-upstream bypass colostomy
- No CRS

Pulmonary embolism at Day 4
Rest of the post operative course uneventful

Day 13 chemotherapy strat again

Folfox Erbitux



A Young man of 32 years old, on APRIL

- we operate April
- PCI index at 20
- 13 regions affected
 - Sigmoid cancer

Douglas pouch resection
cholecystectomy
splenectomy
ileo-colonic resection
anterior resection
and colorectal anastomosis
Double stomia

HIPEC Oxaliplatin 460 mg/M2



- we operate April
- PCI index at 20
- 13 regions affected
 - Sigmoid cancer

No specific morbidity

Douglas pouch resection
cholecystectomy
splenectomy
ileo-colonic resection
anterior resection
and colorectal anastomosis
Double stomia

HIPEC Oxaliplatin 460 mg/M2



- Have a strategy
- Do not make carcinological compromises from the beginning because the response to chemotherapy allows new possibilities



- Diagnosis: November 2007
- Start of Chemo and Treatment: 2007
- Colostomy and second-line chemotherapy
- Surgery and CHIP: April 2008 Chemotherapy:
- Death: March 2010

30 months survival with immediate peritoneal carcinoma

